Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

Gut

Volumn 63, Issue 10, 2014, Pages 1658-1667

  Urribarri, Aura D ^a   Munoz Garrido, Patricia ^b   Perugorria, María J ^b,c,d   Erice, Oihane ^b   Merino Azpitarte, Maite ^b   Arbelaiz, Ander ^b   Lozano, Elisa ^e   Hijona, Elizabeth ^b,c   Jiménez Agüero, Raúl ^b   Fernandez Barrena, Maite G ^a,c   Jimeno, Juan P ^a   Marzioni, Marco ^f   Marin, Jose J G ^c,e   Masyuk, Tatyana V ^g   LaRusso, Nicholas F ^g   Prieto, Jesús ^a,c   Bujanda, Luis ^b,c   Banales, Jesús M ^a,b,c,d,g  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INTERLEUKIN 6; INTERLEUKIN 8; MARIMASTAT; MATRIX METALLOPROTEINASE; MESSENGER RNA; STROMELYSIN; CYTOKINE; ENZYME INHIBITOR; HYDROXAMIC ACID; INTERLEUKIN DERIVATIVE; METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BILE DUCT; CELL CULTURE; CELL EXPANSION; CELLS BY BODY ANATOMY; CHOLANGIOCYTE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER POLYCYSTIC DISEASE; LONG TERM CARE; MALE; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ANIMAL; BILIARY PHYSIOLOGY; CELL MATRIX INTERACTION; CHRONIC LIVER DISEASE; CULTURE TECHNIQUE; CYST; CYTOPHOTOMETRY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOBILIARY DISEASE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BILIARY PHYSIOLOGY; CELL MATRIX INTERACTION; CHRONIC LIVER DISEASE; HEPATOBILIARY DISEASE; INTERLEUKINS;

ANIMALS; BILE DUCTS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CYSTS; CYTOKINES; CYTOPHOTOMETRY; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER DISEASES; MALE; METALLOENDOPEPTIDASES; RATS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84908544836     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305281     Document Type: Article

References (29)

1. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013;10:101-8.
2. Masyuk T, LaRusso N. Polycystic liver disease: new insights into disease pathogenesis. Hepatology 2006;43:906-8.
3. Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011;140:1855-9, 9 e1.
4. Alvaro D, Onori P, Alpini G, et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol 2008;172:321-32.
5. Amura CR, Brodsky KS, Gitomer B, et al. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol 2008;294:C786-96.
6. Fabris L, Cadamuro M, Fiorotto R, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006;43:1001-12.
7. Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004;40:836-46.
8. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292:F905-11.
9. Murray SL, Grubman SA, Perrone RD, et al. Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease. Connect Tissue Res 1996;33:249-56.
10. Waanders E, Van Krieken JH, Lameris AL, et al. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol 2008;21:1293-302.
11. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-33.
12. Sbardella D, Fasciglione GF, Gioia M, et al. Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol Aspects Med 2012;33:119-208.
13. Yasoshima M, Sato Y, Furubo S, et al. Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease. J Pathol 2009;217:442-51.
14. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90.
15. - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56:687-97.
16. Banales JM, Masyuk TV, Gradilone SA, et al. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009;49:160-74.
17. Muff MA, Masyuk TV, Stroope AJ, et al. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of autosomal recessive polycystic kidney disease. Lab Invest 2006;86:940-50.
18. Van Hove I, Lemmens K, Van de Velde S, et al. Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J Neurochem 2012;123:203-16.
19. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383-8.
20. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101-9.
21. Novak KB, Le HD, Christison-Lagay ER, et al. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res 2010;67:257-62.
22. Rosenbaum E, Zahurak M, Sinibaldi V, et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 2005;11:4437-43.
23. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008;173:1637-46.
24. Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008;118:3714-24.
25. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011;12:233.
26. Akira S, Nishio Y, Inoue M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994;77:63-71.
27. Yang Q, Zhang XF, Pollard TD, et al. Arp2/3 complex-dependent actin networks constrain myosin II function in driving retrograde actin flow. J Cell Biol 2012;197:939-56.
28. Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells 1999;17:237-40.
29. Obermuller N, Morente N, Kranzlin B, et al. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001;280:F540-50.